As a research facilitator, the Harvard Stem Cell Institute does not conduct clinical trials and is unable to address individual medical questions.
HSCI's research mission is to help patients, but many years and research dollars are required to move a potential therapeutic through the clinical pipeline. We accelerate the process by:
- Fueling collaborations between academic researchers and clinician-scientists
- Providing the scientific community with shared resources, such as the TransLab at the Center for Human Cell Therapy, The Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, and the Gene Therapy Program at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center
- Partnering with companies and investors to commercialize technologies, including supporting startup formation.
Stem cell treatments: information for patients
The International Society for Stem Cell Research (ISSCR) offers some important information on evaluating stem cell treatments, including a list of suggested questions for patients to discuss with their care providers.
The most comprehensive list of clinical trials for all diseases is published on the National Institute of Health's website, ClinicalTrials.gov.
Additionally, the Alliance for Regenerative Medicine maintains a list of clinical trials and therapies.